← Back to patent-cliff list
Efavirenz
Tier B — Position earlyEfavirenz
Bristol Myers Squibb
Originator
1998
First approval
-
Expiry (public)
$1.61B ▲
Peak sales
Small molecule
Type
Targets：HIV-1 RT
Brand：Stocrin, Sustiva
Indications (approved)：HIV infection
Regional status
US
Phase I
1997-10-01
EU
Withdrawn
China
Approved
2000-06-16
Japan
Approved
2008-04-07
Synthetic routes & intermediates5 routes
Originator routes × 1Optimised (non-patent) × 4Process routes × 0
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
OriginatorRoute 1Steps 6 · Total yield 3.43 g
EFAV-001106-47-8EFAV-0023282-30-2EFAV-00365854-91-3EFAV-004154598-53-5EFAV-0056746-94-7EFAV-006168834-43-3EFAV-007177530-93-7EFAV-00839637-74-6EFAV-009181377-64-0API · Efavirenz
| Code | CAS No. | Intermediate |
|---|---|---|
| EFAV-001 | 106-47-8 | 4-chloroaniline |
| EFAV-002 | 3282-30-2 | pivaloyl chloride |
| EFAV-003 | 65854-91-3 | N-(4-chlorophenyl)pivalamide |
| EFAV-004 | 154598-53-5 | 1-(2-amino-5-chlorophenyl)-2,2,2-trifluoroethanone |
| EFAV-005 | 6746-94-7 | ethynylcyclopropane |
| EFAV-006 | 168834-43-3 | 2-(2-amino-5-chlorophenyl)-4-cyclopropyl-1,1,1-trifluorobut-3-yn-2-ol |
| EFAV-007 | 177530-93-7 | 6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1H-benzo[d][1,3]oxazin-2(4H)-one |
| EFAV-008 | 39637-74-6 | (1S)-4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carbonyl chloride |
| EFAV-009 | 181377-64-0 | (4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1-((4S)-4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carbonyl)-1H-benzo[d][1,3]oxazin-2(4H)-one |
OptimisedRoute 2Steps 5 · Total yield /
EFAV-00365854-91-3EFAV-004154598-53-5EFAV-0056746-94-7EFAV-010824-94-2EFAV-011173676-54-5EFAV-012127641-25-2EFAV-013173676-60-3EFAV-014174819-21-7API · Efavirenz
| Code | CAS No. | Intermediate |
|---|---|---|
| EFAV-003 | 65854-91-3 | N-(4-chlorophenyl)pivalamide |
| EFAV-004 | 154598-53-5 | 1-(2-amino-5-chlorophenyl)-2,2,2-trifluoroethanone |
| EFAV-005 | 6746-94-7 | ethynylcyclopropane |
| EFAV-010 | 824-94-2 | 1-(chloromethyl)-4-methoxybenzene |
| EFAV-011 | 173676-54-5 | 1-(5-chloro-2-((4-methoxybenzyl)amino)phenyl)-2,2,2-trifluoroethanone |
| EFAV-012 | 127641-25-2 | (1R,2S)-1-phenyl-2-(pyrrolidin-1-yl)propan-1-ol |
| EFAV-013 | 173676-60-3 | (S)-2-(5-chloro-2-((4-methoxybenzyl)amino)phenyl)-4-cyclopropyl-1,1,1-trifluorobut-3-yn-2-ol |
| EFAV-014 | 174819-21-7 | (S)-6-chloro-4-(cyclopropylethynyl)-1-(4-methoxybenzyl)-4-(trifluoromethyl)-1H-benzo[d][1,3]oxazin-2(4H)-one |
OptimisedRoute 3Steps 5 · Total yield /
EFAV-0056746-94-7EFAV-006168834-43-3EFAV-0156628-86-0EFAV-0161352784-88-3EFAV-0171352784-89-4EFAV-0181486480-83-4EFAV-0191352784-90-7EFAV-0207693-46-1API · Efavirenz
| Code | CAS No. | Intermediate |
|---|---|---|
| EFAV-005 | 6746-94-7 | ethynylcyclopropane |
| EFAV-006 | 168834-43-3 | 2-(2-amino-5-chlorophenyl)-4-cyclopropyl-1,1,1-trifluorobut-3-yn-2-ol |
| EFAV-015 | 6628-86-0 | 5-chloro-2-nitrobenzaldehyde |
| EFAV-016 | 1352784-88-3 | 1-(5-chloro-2-nitrophenyl)-3-cyclopropylprop-2-yn-1-ol |
| EFAV-017 | 1352784-89-4 | 1-(5-chloro-2-nitrophenyl)-3-cyclopropylprop-2-yn-1-one |
| EFAV-018 | 1486480-83-4 | (1R,2R,4R,5S)-1-(3,5-bis(trifluoromethyl)benzyl)-2-((R)-hydroxy(quinolin-4-yl)methyl)-5-vinylquinuclidin-1-ium bromide |
| EFAV-019 | 1352784-90-7 | (S)-2-(5-chloro-2-nitrophenyl)-4-cyclopropyl-1,1,1-trifluorobut-3-yn-2-ol |
| EFAV-020 | 7693-46-1 | 4-nitrophenyl carbonochloridate |
OptimisedRoute 4Steps 4 · Total yield 120.00 mg
EFAV-0056746-94-7EFAV-021106-46-7EFAV-022431-47-0EFAV-023886371-22-8EFAV-0241381993-91-4EFAV-0251381993-88-9EFAV-0261381993-90-3API · Efavirenz
| Code | CAS No. | Intermediate |
|---|---|---|
| EFAV-005 | 6746-94-7 | ethynylcyclopropane |
| EFAV-021 | 106-46-7 | 1,4-dichlorobenzene |
| EFAV-022 | 431-47-0 | methyl 2,2,2-trifluoroacetate |
| EFAV-023 | 886371-22-8 | 1-(2,5-dichlorophenyl)-2,2,2-trifluoroethanone |
| EFAV-024 | 1381993-91-4 | (R)-N-(1-hydroxy-1,1-diphenylpropan-2-yl)naphthalene-2-sulfonamide |
| EFAV-025 | 1381993-88-9 | (S)-4-cyclopropyl-2-(2,5-dichlorophenyl)-1,1,1-trifluorobut-3-yn-2-ol |
| EFAV-026 | 1381993-90-3 | (S)-4-cyclopropyl-2-(2,5-dichlorophenyl)-1,1,1-trifluorobut-3-yn-2-yl carbamate |
OptimisedRoute 5Steps 3 · Total yield /
EFAV-0056746-94-7EFAV-027173676-59-0EFAV-028541-41-3EFAV-0291389253-14-8EFAV-0301315468-11-1EFAV-031861968-41-4EFAV-032115-11-7API · Efavirenz
| Code | CAS No. | Intermediate |
|---|---|---|
| EFAV-005 | 6746-94-7 | ethynylcyclopropane |
| EFAV-027 | 173676-59-0 | 1-(2-amino-5-chlorophenyl)-2,2,2-trifluoroethanone hydrochloride |
| EFAV-028 | 541-41-3 | ethyl carbonochloridate |
| EFAV-029 | 1389253-14-8 | ethyl (4-chloro-2-(2,2,2-trifluoroacetyl)phenyl)carbamate |
| EFAV-030 | 1315468-11-1 | (1R,2R)-2-(benzyl(methyl)amino)-3-(tert-butoxy)-1-(4-nitrophenyl)propan-1-ol |
| EFAV-031 | 861968-41-4 | (1R,2R)-2-(benzyl(methyl)amino)-1-(4-nitrophenyl)propane-1,3-diol |
| EFAV-032 | 115-11-7 | 2-methylprop-1-ene |
Frequently asked questions
What are the approved indications of Efavirenz?
Approved indications include: HIV infection.
When does the Efavirenz patent expire?
No public expiry year is available for Efavirenz yet; this page updates once verified.
How many synthesis routes are recorded for Efavirenz?
5 synthesis routes are recorded; the shortest is 3 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Efavirenz intermediates?
All intermediates in Efavirenz routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Efavirenz intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29